Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.
about
Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiencyClinical use of pharmacogenomic tests in 2009A practical strategy to design and develop an isoform-specific fluorescent probe for a target enzyme: CYP1A1 as a case study.Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTGeneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Marginal increase of sunitinib exposure by grapefruit juice.Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patientsPopulation pharmacokinetics of midazolam and its metabolites in overweight and obese adolescentsLimited frequency of the CYP2C19*17 allele and its minor role in a Japanese populationEffects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping indexPharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" ProblemPharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceModels of drug-induced liver injury for evaluation of phytotherapeutics and other natural products.Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in ratsGenetic variability in CYP2A6 and the pharmacokinetics of nicotine.New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail.CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores.Breath tests to phenotype drug disposition in oncology.Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).Alternative Sampling Strategies for Cytochrome P450 Phenotyping.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults.CYP3A activity: towards dose adaptation to the individual.Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.Cytochrome P450 2U1, a very peculiar member of the human P450s family.Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugs.Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.Use of microdose phenotyping to individualise dosing of patients.Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilutionValidation of individual quantitative methods for determination of cytochrome P450 probe substrates in human dried blood spots with HPLC-MS/MS.Prediction of drug response and safety in clinical practice.Effect of nicotine on cytochrome P450 1A2 activity.
P2860
Q24609157-93A3BF2C-5F54-4A6C-ACB7-66EA17203708Q24657536-417CEADD-556A-4B86-8E1A-AB3547DB5641Q33662661-1B2F6B14-70A0-46B0-8E7B-E00412814942Q34012749-BFEBE9D7-DCB6-4603-897E-BCB6FC006912Q34116690-01612FA7-F8DA-4460-835B-1FE8CAAF221CQ34594877-8546095F-DBC4-4CC6-8EF8-6C72705232E0Q35023726-49561EC4-C8E2-48D0-9F58-71D51C99D6ADQ35210306-2353013B-E45E-4517-94E6-705B95E833E2Q35904433-8CB8842F-E86D-46D2-A4F2-F56BC51A9D18Q36243677-3553F143-899E-45A3-B840-4B0716252242Q36243689-750C5E92-E263-4CB2-B6B4-2D67A03FF01EQ36535932-BE595D69-3252-4BB0-B77B-CA8ADEFB5A18Q36562516-B69F5715-91CC-4F0F-B6C2-7BC388C16671Q36634077-2EAD718C-17C4-4EC9-B112-A5B255C584B1Q36657589-D3636F52-6013-4CB9-9F52-F3D81A089E47Q36718265-F5834039-C361-4CA5-9BD0-E358DB9A6436Q36765121-71855FE5-8FFB-48C2-8082-E1AA1505A035Q36989832-4DB11B1E-150F-4E54-81BE-C793782AFC04Q37124261-B5946B03-D466-40B6-9B06-7BA1257B163BQ37399585-5919AD1E-04A1-4F82-9AEF-F84D9EC4B34DQ37424646-6E209D23-9109-41B4-9009-B795388DB65BQ37492051-ADAC3D7B-B06F-4C84-9D3E-4B5F03B93647Q38122635-19227EEE-68EF-4D6D-B98E-372C84081B82Q38253565-5CD3B266-1558-4734-8591-6B7B80EC2189Q38560254-B89C191C-C93C-497A-8CB4-4CDB02C0730CQ38634986-18F0D1BE-ED02-4A85-B36C-9FCC7C9C2360Q38635521-2C094A65-A558-4F5C-A942-B47CC971955FQ38763583-111E7926-7752-4B92-8A24-6A926AEA6A26Q38818845-9D88A827-C97D-46CF-94F8-CA4BD0F1BE50Q39023075-F6D54563-76CC-4D58-823A-A97DDCB21336Q40186641-47946A23-3239-4DA3-8D56-1ED0EA506F94Q40192653-D987513A-E2F4-4AF3-B3AD-5400C0FF0E52Q40405015-B97B657F-47E8-4BE7-963D-70534D86B0ABQ40929413-D3B2B314-50BC-4838-A4D9-E474F21C5685Q40996401-009F94A3-35E6-4B66-905D-F0599442A02DQ41737190-1DE5964F-FAA3-4707-98FB-B40771498A8BQ42758567-3DA34443-7C2F-415C-BFE3-E688F28137D1Q42806737-A2818C7A-25AC-46C8-9E49-915D66575180Q42870458-2696FE39-7E13-4414-BB50-E74D3B4F1A1DQ43024689-73365E61-BB9C-4FA7-96B5-3F2DAD0616FC
P2860
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Appropriate phenotyping proced ...... se in the "cocktail" approach.
@ast
Appropriate phenotyping proced ...... se in the "cocktail" approach.
@en
type
label
Appropriate phenotyping proced ...... se in the "cocktail" approach.
@ast
Appropriate phenotyping proced ...... se in the "cocktail" approach.
@en
altLabel
Appropriate Phenotyping Proced ...... Use in the “Cocktail” Approach
@en
prefLabel
Appropriate phenotyping proced ...... se in the "cocktail" approach.
@ast
Appropriate phenotyping proced ...... se in the "cocktail" approach.
@en
P2093
P356
P1476
Appropriate phenotyping proced ...... se in the "cocktail" approach.
@en
P2093
P304
P356
10.1038/SJ.CLPT.6100050
P407
P577
2007-02-01T00:00:00Z